ABSTRACT
The Adaptive Logistic Model (ALM) of epidemics incorporates the results of infection mitigation effects on the course of an epidemic, and well describes the histories of the COVID-19 epidemics in many countries, including the United States. In particular, it is much more successful than is a basic logistic model. However, in the U.S. these mitigation efforts have recently been relaxed in many places, resulting in the second peak in infections that started in late May of 2020. In this paper the ALM is modified to account for the relaxation of these mitigation effects, leading to the Adaptive Logistic Model 2 (ALM-2). The ALM-2 is then used to understand quantitatively the second peak of COVID-19 cases. The ALM-2 is also successfully applied to the data on deaths even though they do not yet show a second peak.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB review not required for this study which uses only publicly available data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All of the data come from the European Centre for Prevention and Control of Disease.
